Commentary

Video

Addressing CNS Involvement in ROS1+ NSCLC

Author(s):

Charu Aggarwal, MD, MPH,Geoffrey Liu, MSc, MD

Fact checked by:

Chris Ryan

Charu Aggarwal, MD, MPH, and Geoffrey Liu, MSc, MD, discuss CNS involvement in ROS1-positive non–small cell lung cancer.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
View More
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity
View More
Related Content
Non–Small Cell Lung Cancer | Image by Ashling Wahner & MJH Life Sciences Using AI
June 13th 2025

TT125-802 Demonstrates Potential in Advanced NSCLC and Solid Tumors

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.
June 11th 2025

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
October 16th 2024

How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD

ES-SCLC | Image by: Ashling Wahner & MJH Life Sciences Using AI
June 10th 2025

First-Line Lurbinectedin Plus Atezolizumab Maintenance Under Priority Review for ES-SCLC

Suresh S. Ramalingam, MD, FACP, FASCO
June 9th 2025

Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List